StockData

Aquestive Therapeutics vs Ocular Therapeutix

AQST and OCUL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AQST and OCUL compare

Ocular Therapeutix is the larger company, worth 2.8 times as much as Aquestive Therapeutics ($1.3B against $464M).

Aquestive Therapeutics grew revenue faster over the last twelve months (22.6% versus −8.1% for Ocular Therapeutix).

Aquestive Therapeutics keeps more of each dollar of sales as profit, with a net margin of −145% compared with −579% at Ocular Therapeutix.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAQSTOCUL
Size and price
Market cap$464M$1.3B
Share price$3.70$6.02
Change, 1 year−31.4%−46.7%
Change, 5 years−41.9%−8.0%
Beta (5Y)1.201.53
Employees147325
StockData Score
Total score33
Valuation score00
Growth score2 (better)0
Performance score00
Health score13 (better)
Dividend score00
Valuation
P/S8.6× (better)25.4×
P/B–2.5×
FCF yield−9.9% (better)−19.3%
Fair value–$5.44
Margin of safety–−10.6%
Growth
Revenue growth (TTM)22.6% (better)−8.1%
Revenue growth, 5Y average−0.58%24.4% (better)
Profitability
Gross margin67.0%87.1% (better)
Operating margin−97.5% (better)−603%
Net margin−145% (better)−579%
FCF margin−85.0% (better)−490%
Return on equity–−73.0%
Financial health
Debt / equity–0.14
Interest coverage−4.7× (better)−27.5×
Current ratio7.1913.11 (better)
Altman Z-score−3.572.08 (better)
Piotroski F-score24 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions57.4%94.4%
Held by insiders3.2%2.9%
Insider net buying, 12 months−$2.3M (better)−$2.5M
Short interest, % of float24.1%13.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.